https://www.selleckchem.com/products/arn-509.html
To compare the efficacy and safety between half-dose photodynamic therapy (PDT) and eplerenone for treating chronic central serous chorioretinopathy (cCSC). Multicenter, open-label, randomized controlled trial. This investigator-initiated trial was conducted in 3 academic medical centers in the Netherlands. Eligible patients were randomized at a 11 ratio to receive either indocyanine green angiography-guided half-dose PDT or oral eplerenone for 12 weeks. Both anatomical and functional outcomes were evaluated at 3 months after the start
Like
Comment
Share
